Wisconsin health officials report that approximately 30% of invasive meningococcal disease cases diagnosed in the state since June 2024 display resistance to ciprofloxacin, alongside an independent scientific review announced by the Vaccine Integrity Project.
Wisconsin Confirms Fifth Resistant Infection
State health officials in Wisconsin have confirmed a new case of invasive meningococcal disease caused by ciprofloxacin-resistant Neisseria meningitidis. This infection marks the fifth resistant case identified in the state since June 2024. Approximately 30% of invasive meningococcal disease cases diagnosed in Wisconsin during this timeframe display resistance to ciprofloxacin, according to state health reporting.
The bacterial infection spreads through close, direct contact with respiratory and throat secretions, such as saliva. Transmission typically happens when individuals share items that come into contact with the mouth, including water bottles, eating utensils, lip balm, cigarettes, and smoking materials. Casual contact or breathing air in a space where an infected person has been does not transmit the bacteria, though prolonged time in shared spaces like roommates can occasionally facilitate spread.
Wisconsin is following guidance from the Centers for Disease Control and Prevention (CDC) to discontinue using ciprofloxacin for the prophylaxis of close contacts because of these resistant strains. This restriction remains in place until 24 months pass without a single reported case caused by ciprofloxacin-resistant strains. Health authorities note that antibiotic prophylaxis with ciprofloxacin in regions with documented resistance can lead directly to prophylaxis failure.
University of Minnesota Evaluates Vaccines
The Vaccine Integrity Project (VIP) at the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP) announced its next independent scientific evaluation. The project will examine existing scientific evidence on meningococcal and pneumococcal vaccines for children and young adults.
Federal Guidelines Narrow Meningococcal Vaccine Recommendations
Under guidelines ushered in by Health and Human Services Secretary Robert F. Kennedy Jr., federal recommendations distinguish sharply between different formulations. While the pneumococcal vaccine remains recommended for all children, federal guidance for meningococcal shots has narrowed.
The MenB and MenACWY vaccines are now recommended only for specific high-risk groups or populations, while other meningococcal options have been relegated to immunization based on shared clinical decision-making.
Those federal adjustments contrast with ongoing professional guidance.
Osterholm added further context regarding the current regulatory climate, stating that the federal vaccine review and recommendation process is not functioning as it historically has. Despite the federal reclassifications, the American Academy of Pediatrics maintains its recommendation that all children and adolescents receive the vaccines.
Meningococcal Infections Cause Permanent Injury or Death
Public health agencies track an uptick in infections since 2021, driven largely by the vaccine-preventable serogroup Y, while cases of invasive meningococcal disease remain rare across the United States. The infection carries severe risks for those who contract it.
Data from the Centers for Disease Control and Prevention indicates that 10% to 15% of meningococcal infections prove fatal. Between 10% and 20% of survivors experience permanent aftereffects, including brain injury, limb amputation, or hearing loss.